Suzanne Winter
President, CEO & Director
Good afternoon, everyone, and welcome to Accuray’s Analyst briefing. We’re coming to you from the ASTRO conference in San Francisco for 2025. We’ll be leading a discussion about leading in the adaptive era of radiation medicine. I want to welcome everyone. It’s absolutely a privilege to be here with a distinguished group of our global key opinion leaders in radiation oncology as well as our research analysts and shareholders who are joining us virtually. Our analysts that cover medtech and radiation oncology market, and they write notes for investors and advise on investment decisions. You’re all experts and who — how we shape, how we understand innovation in medical technology and how we bridge clinical insight, patient outcomes and investment perspectives.
As you know, at Accuray, we believe our role is not just to build devices, but to advance medicine by partnering with clinicians and researchers who set the standard of care. Today, we’re going to have an open dialogue about the trends in adaptive radiation medicine treatment. We’ll be sharing science behind the technology and hearing perspectives from our esteemed panel, and we’ll be exploring how we can make the greatest impact for patients and health care systems to deliver clinical and economic value. So thank you for taking the time to be here. We’ll dive into the conversation. I’ll make a few opening remarks, and then we’ll go right into the discussion.
Let’s start with our safe harbor statement. And again, this is a presentation that
#Accuray #Incorporated #ARAY #ShareholderAnalyst #Call #Transcript